• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Daratumumab appears safe for patients with multiple myeloma, advanced renal insufficiency

by | Jun 11, 2022 | Uncategorized

Source: Healio News CHICAGO — Daratumumab appeared safe for patients with multiple myeloma who had advanced renal insufficiency, according to study results presented at ASCO Annual Meeting.“The take-home message from our study is that there was no significant impact...

Addition Stem Cell Transplant Boosts Outcomes for Common Myeloma Regimen

by | Jun 10, 2022 | Uncategorized

Source: Cure Today articles Patients who underwent Revlimid, Velcade, and dexamethasone therapy followed by maintenance Revlimid, tended to have better outcomes when they underwent autologous stem cell transplant. Read More

Adding Darzalex to Popular Multiple Myeloma Treatment Regimen May Lead to Durable Responses

by | Jun 7, 2022 | Uncategorized

Source: Cure Today articles Patients with multiple myeloma were more likely to have no traceable amounts of disease left when Darzalex was added to a treatment regimen of Revlimid, Velcade and dexamethasone. Read More

CAR-T shows ‘impressive efficacy’ for patients with advanced multiple myeloma

by | Jun 6, 2022 | Uncategorized

Source: Healio News CHICAGO — A novel chimeric antigen receptor T-cell therapy has elicited objective responses among the first eight patients who received the treatment, according to results from the phase 1 POLARIS trial presented at ASCO Annual Meeting.Use of...

Investigational CAR-T shows promise for advanced multiple myeloma

by | Jun 5, 2022 | Uncategorized

Source: Healio News CHICAGO — A single dose of a novel chimeric antigen receptor T-cell therapy induced objective response among all treated patients with relapsed or refractory multiple myeloma, according to study results presented at ASCO Annual Meeting.The...

Triplet induction, autologous HSCT, lenalidomide maintenance extend PFS in multiple myeloma

by | Jun 5, 2022 | Uncategorized

Source: Healio News CHICAGO — Lenalidomide, bortezomib and dexamethasone plus autologous stem cell transplantation and lenalidomide-based maintenance conferred a significant PFS benefit among patients with newly diagnosed multiple myeloma.However, no OS benefit had...
« Older Entries
Next Entries »

Recent Content

  • A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast
  • Talquetamab and Teclistamab Achieve Deep, Durable Responses in Patients With Relapsed, Refractory Multiple Myeloma
  • Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study
  • Fixed-Dose Subcutaneous Sarclisa Combo is Non-Inferior to IV Sarclisa in R/R Myeloma
  • Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma
  • Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
  • IVIG Supplementation Reduces Infection Risk in Patients With Multiple Myeloma Receiving Teclistamab
  • Combination induces durable responses in advanced multiple myeloma
  • Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes
  • Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT